Full Text
PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA)

Abstract

Authors

H Miadi-Fargier B Fautrel M Maravic JP Daures AL Ollivier C Le Pen F Maurel

Back to Volume 11, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×